# 4D pharma plc Clinical Update – Blautix IND

- Link: https://www.directorstalkinterviews.com/4d-pharma-plc-clinical-update-blautix-ind/412750714
- Published: 2018-05-08T08:04:46+01:00
- Author: Giles Arbor

**4D pharma plc** (LON:DDDD), a pharmaceutical company leading the development of
live biotherapeutics, has today announced that the Company has submitted, and the
U.S. Food and Drug Administration (FDA) has cleared, an Investigational New Drug
Application for Blautix, the Company’s live biotherapeutic for the treatment of 
Irritable Bowel Syndrome (IBS). Enrolment in the Phase 2 study is expected to commence
in the second half of 2018.

The double-blind, placebo-controlled multicentre Phase 2 study will evaluate the
efficacy and safety of Blautix in patients with IBS with constipation (IBS-C) and
IBS with diarrhoea (IBS-D). 4D has consulted with the FDA on the design of the study.
Up to 500 patients will receive either Blautix or placebo daily for 8 weeks. The
primary endpoint will be the Overall Response rate, defined as the proportion of
patients reporting an improvement in their weekly cohort-specific symptoms (abdominal
pain and stool frequency or consistency) for at least 4 out of 8 weeks. A range 
of secondary efficacy endpoints will also be assessed, as well as the effects of
Blautix on the gut microbiome.

> **Dr. Alex Stevenson, 4D Pharma Plc Chief Scientific Officer, commented:** “We
> are delighted to advance Blautix into this important proof-of-concept study, which
> brings us another step closer to bringing a novel treatment regime to patients.
> Despite affecting up to 15% of the population, and a market forecast to be worth
> more than $2.5 billion by 2024*, IBS is poorly addressed with current therapies,
> which only target the symptoms of the disease rather than tackling the underlying
> causes. By targeting the microbiome, Blautix has the potential to make a real 
> difference for patients and could represent a new era in the treatment of IBS.”

Share on:
